Amerikanische Gesellschaft für Hirudotherapie

National Centre for Expertise of Medicines and Medical Devices

NCEPM · Kazakhstan · asia pacific

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Kazakhstan's National Centre for Expertise of Medicines and Medical Devices — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
asia pacific
Country
Kazakhstan
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Kazakhstani national medicines and medical-device law
  • Eurasian Economic Union (EAEU) medical-device harmonisation rules as applicable

Prescriber Requirements

  • Kazakhstani-licensed physician (дәрігер) under Ministry of Health authority — order required for any biomedical device application
  • Traditional medicine practitioner scope under Kazakhstani national law not independently verified by ASH

Supply Chain & GMP

NCEPM registration as applicable; Kazakh and Russian-language labelling. Standard cold-chain conditions.

Import/Export Rules

Import licence requirements; EAEU intra-union movement rules may apply; veterinary clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Kazakhstan participates in EAEU regulatory harmonisation alongside Russia, Belarus, Armenia, and Kyrgyzstan; the practical interaction between EAEU and national-level NCEPM review for live-organism devices has not been independently mapped by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.